ArvinderSinghBirMD

Oncology • Huntington, WV

Physician

Join to view full profile

Dr. Bir is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bir's full profile

Already have an account?

Office
3075 US Route 60
Huntington, WV 25705
Phone+1 304-528-4600

Fax+1 304-697-0856

Summary

Dr. Arvinder Bir is an oncologist based in Huntington, WV. He completed his residency and fellowships in Hematology and Medical Oncology at the University at Buffalo after graduating from LLRM Medical College in 1999. Dr. Bir is a distinguished author, with several publications in medical journals - including Cancer Chemotherapy and Pharmacology and Anticancer Research. He's also been involved in numerous clinical trials, primarily related to lung cancer and breast cancer. Dr. Bir's commitment to rigorous standards of care is demonstrated by his repeated achievement of CMS Meaningful Use Stage 1 Certification from Intergy EHR.

Education & Training

University at BuffaloFellowship, Hematology and Medical Oncology, 2007 - 2008
University at BuffaloFellowship, Hematology and Medical Oncology, 2005 - 2006
University at BuffaloResidency, Internal Medicine, 2002 - 2005
LLRM Medical CollegeClass of 1999

Certifications & Licensure

CA State Medical License 2011 - Present
FL State Medical License 2023 - 2027
KY State Medical License 2023 - 2026
WV State Medical License 2008 - 2026
NY State Medical License 2005 - 2015
American Board of Internal Medicine Hematology
American Board of Internal Medicine Hospice and Palliative Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Intergy EHR, Vitera Healthcare Solutions, LLC, 2013
CMS Meaningful Use Stage 1 Certification Intergy EHR, Greenway Health, LLC, 2011-2012

Clinical Trials

CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Start of enrollment: 2010 Nov 01
Completed
Phase 4
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Evaluation of Anti-Angiogenic Therapy Combined with Immunotherapy and Chemotherapy as a Strategy to Treat Locally Advanced and Metastatic Non-Small-Cell Lung Cancer.
Mahmoud Abdallah, Rick Voland, Malcolm Decamp, John Flickinger, Toni Pacioles
Cancers. 2024-12-17
16 citations
Serological immune responses to influenza vaccine in patients with colorectal cancer.
Ajithkumar Puthillath, Donald L. Trump, Chris Andrews, Arvinder Bir, Karen Romano
Cancer Chemotherapy and Pharmacology. 2011-01-01
10 citations
Spontaneous regression of colorectal cancer metastatic to retroperitoneal lymph nodes.
Arvinder Bir, Ahmad Fora, Charles LeVea, Marwan Fakih
Anticancer Research. 2009-02-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member